Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics higher as it files patent application for potential eczema treatment

The AIM-listed skin health company said the application covered the use of its SkinBiotix technology for increasing filaggrin levels in the skin
Scratching skin on arm
Filaggrin is vital for cells to mature properly into the tough outer layer of the skin

SkinBioTherapeutics PLC (LON:SBTX) shares rose on Monday on news the firm has filed a patent application for a potential treatment that could help skin conditions such as eczema.

The AIM-listed skin health company said in a statement that the application covered the use of its SkinBiotix technology for increasing filaggrin levels in the skin.

READ: SkinBioTherapeutics finalises plans for cosmetic study; updates on manufacturing scale-up

Filaggrin is a protein that is vital for cells to mature properly into the tough outer layer of the skin, with deficiencies leading to dryness and irritation as well as the potential development of conditions such as eczema.

The company said research in its labs had shown that SkinBiotix could significantly increase the amount of filaggrin in human skin models.

This is the second successful test of the group's technology, following earlier proof that SkinBiotix increases the 'tight junction' which exists in the inner layer of skin.

The company added that the observation that the technology can improve both the surface and inner layers of skin suggests that SkinBiotix would be therapeutically useful in a range of conditions, such as eczema.

SkinBioTherapeutics has already finalised plans for a human study around the cosmetic application of its SkinBiotix technology, which is expected to be carried out in the third quarter of this year.

SkinBiotix continuing to prove its uniqueness

Dr Cath O’Neill, chief executive of SkinBioTherapeutics, said: "SkinBiotix is continuing to prove its uniqueness as a platform via scientific testing. Following the successful work in skin models on filaggrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent.

"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatalogical markets."

In a note to clients, analysts at 'house' broker Northland Capital commented: “These findings regarding filaggrin production combined with previous observations on tight junctions indicate that the SkinBiotix platform has beneficial properties on both the surface and inner layers of skin and could be therapeutically useful in a range of skin conditions, including eczema.”

They added: “The filing of this patent shows the Company is continuing to protect its IP portfolio surrounding its SkinBiotix technology.

“The Company’s first patent (covering the use of bacteria and lysates in the treatment of skin in health and disease) has been granted in Australia, New Zealand and Russia with active prosecution progressing in Europe, USA and China.”

In early afternoon trading, SkinBioTherapeutics shares were up 6.3% at 17p.

-- Adds analyst comment; updates share price --

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use